文献速递胸部肿瘤

老年转移性非小细胞肺癌全身治疗率的人群研究

Rates of Systemic Treatment for Metastatic Non-Small Cell Lung Cancer Among Older Adults.
PubMed 文献 · JAMA Oncol · 2026-01-01

结果显示46.8%患者曾接受全身治疗,治疗比例随时间仅轻微增加;肿瘤专科转诊与治疗显著相关,80岁以上、组织学类型未特指者治疗率较低。

要点

  • 老年mNSCLC患者全身治疗率仅46.8%,近二十年来改善有限。
  • 肿瘤专科转诊者180天累积治疗发生率提高30.3%。
  • 80岁以上患者较65-69岁者180天累积治疗发生率低15.4%。

核心结论

  • 尽管近几十年治疗进展显著,近半数老年mNSCLC患者从未接受全身治疗,且治疗比例仅轻微改善。
  • 临床特征最优的患者中约五分之一仍未接受全身治疗。

研究设计与样本

  • 数据分析时间为2025年10月至2026年2月,采用竞争风险比例风险模型分析全身治疗接受情况。

主要发现

  • 2006至2021年间治疗比例仅轻微增加。
  • 竞争风险模型中,肿瘤专科转诊与治疗相关(HR 2.5;95%CI 2.41-2.67;P<.001),对应180天累积治疗发生率(CIF180)增加30.3%。
  • 生物标志物检测者CIF180增加17.8%;80岁以上较65-69岁者CIF180降低15.4%;组织学未特指者较腺癌CIF180降低12.8%。

临床怎么用

  • 应重视肿瘤专科转诊,其与老年mNSCLC患者全身治疗率显著提高相关。
  • 生物标志物检测可能与更高的治疗接受率相关,需在适宜患者中推广。
  • 高龄(>80岁)和组织学类型未特指与较低治疗率相关,需关注这些人群的治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Metastatic non-small cell lung cancer (mNSCLC) has very high mortality rates, and comprises approximately half of new cases of lung cancer; however, highly effective and better tolerated treatments have become available in recent decades. Nevertheless, population-level treatment of mNSCLC is poorly characterized in the era of rapid treatment advances. OBJECTIVE: To characterize treatment rates, trends, and factors associated with treatment of mNSCLC. DESIGN, SETTING, AND PARTICIPANTS: This population-based study used linked Surveillance Epidemiology and End Results (SEER) and Medicare claims data and the analysis included patients 65 years and older diagnosed with mNSCLC from January 2006 to December 2021. Data were analyzed from October 2025 to February 2026. EXPOSURES: Sociodemographic variables, comorbidity burden, histologic type, referral to subspecialist, enrollment in Medicare Part D, and biomarker testing. MAIN OUTCOMES: The primary outcome was receipt of systemic treatment. Statistical analyses included summary statistics and a competing risk proportional hazards model for receipt of systemic treatment. RESULTS: Of 254 611 patients with mNSCLC, the cohort median (IQR) age was 73 (68-80) years, with 133 635 (52.5%) male individuals; a total of 9512 (3.7%) were Asian, 26 546 (10.4%) were Black, 4553 (1.8%) were Hispanic, 205 381 (80.7%) were White, and 8619 (3.4%) were another or unknown race. A total of 119 197 patients (46.8%) ever received systemic treatment. Of the 100 367 (39.8%) who died within 90 days of diagnosis, 13.2% were treated compared with 69% of those surviving more than 90 days. The treated proportion increased only slightly between 2006 and 2021. In a competing risk model, referral to oncology specialists was associated with treatment (hazard ratio [HR], 2.5; 95% CI, 2.41-2.67; P < .001) which corresponded to a 30.3% greater cumulative incidence of treatment at 180 days (CIF180) compared with those without a referral. Similarly, those with biomarker testing had a 17.8% greater CIF180, whereas those older than 80 years had a 15.4% lower CIF180 compared to those aged 65 to 69 years. Patients with NSCLC not otherwise specified histologic findings had a 12.8% lower CIF180 compared with those with adenocarcinoma histologic findings. Other factors associated with significant but smaller differences in receipt of treatment included comorbidity burden, marital status, Medicare Part C or Part D coverage, rurality, and race and ethnicity. CONCLUSIONS AND RELEVANCE: In this cohort study of older adults with mNSCLC, despite advances in therapy in recent decades, almost half of patients never received systemic therapy, and the proportion treated only minimally improved over time. Approximately one-fifth of those with the most favorable clinical profiles did not receive systemic therapy.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Fox AH, Ward RC, Alexander M, et al. Rates of Systemic Treatment for Metastatic Non-Small Cell Lung Cancer Among Older Adults. JAMA Oncol. 2026. PMID: 42096214. doi:10.1001/jamaoncol.2026.1080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。